Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: Analysis using fixed-effects linear regression model-Reference-Cited by-同舟云学术

Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: Analysis using fixed-effects linear regression model

Published:2023-01 Issue: Volume:578 Page:111-116
ISSN:0042-6822
Container-title:Virology
language:en
Short-container-title:Virology

Author:

Dehgani-Mobaraki Puya^ORCID,Wang Chao^ORCID,Floridi Alessandro,Floridi Emanuela,Dawoodi Sunny,Zaidi Asiya K.^ORCID

Funder

U.S. Food and Drug Administration

Publisher

Elsevier BV

Subject

Virology

Reference26 articles.

1. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy;Abu-Raddad;EClinicalMedicine,2021

2. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset;Anand;Cell Rep Med,2021

3. Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination;Assis;npj Vaccines,2021

4. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients;Azzi;EBioMedicine,2021

5. Clinical and Immunological Responses after SARS-CoV-2 Infection Causing COVID-19 - Full Text View,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durability of SARS-CoV-2 IgG Antibodies: Insights from a Longitudinal Study, Puerto Rico;2024-08-03

2. SARS-CoV-2 Antibody Level after Homologous and Heterologous Booster Vaccines: an 18-month Longitudinal Observational Cohort Study in Indonesia;The Open Public Health Journal;2024-07-31

3. Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study;Viruses;2023-11-13

4. Immune response - genesis, duration, and strength in patients with moderate and severe coronavirus infection of different age groups;PHARMACIA;2023